Clinical development of pharmacologic agents for acute heart failure syndromes: A proposal for a mechanistic translational phase

American Heart Journal

Volumn 161, Issue 2, 2011, Pages 224-232

  Gheorghiade, Mihai ^a   Pang, Peter S ^a   O'Connor, Christopher M ^b   Prasad, Krishna ^c   McMurray, John ^d   Teerlink, John R ^e   Fiuzat, Mona ^b   Sabbah, Hani ^f   Komajda, Michel ^g  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; LEVOSIMENDAN; NESIRITIDE; ROLOFYLLINE; TEZOSENTAN; TOLVAPTAN;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE SYNDROME; ARTICLE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DYSPNEA; HEART FAILURE; HEMODYNAMIC MONITORING; HUMAN; NONHUMAN; OXYGEN SATURATION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STANDARDIZATION; URINE VOLUME; WEIGHT REDUCTION;

ACUTE DISEASE; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; SYNDROME; TRANSLATIONAL RESEARCH;

EID: 79851511096     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.10.023     Document Type: Article

References (47)

1. Gheorghiade M., Zannad F., and Sopko G. Acute heart failure syndromes: current state and framework for future research Circulation 112 2005 3958 3968 (Pubitemid 43739494)
2. Dickstein K., Cohen-Solal A., and Filippatos G. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J 29 2008 2388 2442
3. Fang J., Mensah G.A., and Croft J.B. Heart failure-related hospitalization in the U.S., 1979 to 2004 J Am Coll Cardiol 52 2008 428 434 (Pubitemid 352040814)
4. Hunt S.A., Abraham W.T., and Chin M.H. Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation J Am Coll Cardiol. 53 2009 e1 e90
5. Lloyd-Jones D., Adams R.J., and Brown T.M. Heart disease and stroke statistics-2010 update: a report from the American Heart Association Circulation 121 2010 e46 e215
6. Jencks S.F., Williams M.V., and Coleman E.A. Rehospitalizations among patients in the Medicare fee-for-service program N Engl J Med 360 2009 1418 1428
7. Bueno H., Ross J.S., and Wang Y. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006 JAMA 303 2010 2141 2147
8. Gheorghiade M., Abraham W.T., and Albert N.M. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure JAMA 296 2006 2217 2226 (Pubitemid 44708052)
9. Fonarow G.C., and Peterson E.D. Heart failure performance measures and outcomes: real or illusory gains JAMA 302 2009 792 794
10. Cuffe M.S., Califf R.M., and Adams K.F. Jr Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial Journal of the American Medical Association 287 2002 1541 1547 (Pubitemid 34269999)
11. Gheorghiade M., Konstam M.A., and Burnett J.C. Jr Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials JAMA 297 2007 1332 1343 (Pubitemid 46513234)
12. Konstam M.A., Gheorghiade M., and Burnett J.C. Jr Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial JAMA 297 2007 1319 1331 (Pubitemid 46513233)
13. McMurray J.J.V., Teerlink J.R., and Cotter G. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials JAMA 298 2007 2009 2019 (Pubitemid 350074798)
14. Mebazaa A., Nieminen M.S., and Packer M. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial JAMA 297 2007 1883 1891 (Pubitemid 46707842)
15. Sackner-Bernstein J., Kowalski M., and Fox M. Short-term risk of death after treatment with nesiritide for decompensated heart failure JAMA 293 2005 1900 1905
16. Sackner-Bernstein J.D., Kowalski M., and Fox M. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials JAMA 293 2005 1900 1905 (Pubitemid 40548187)
17. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure Circulation 111 2005 1487 1491 (Pubitemid 40470642)
18. VMAC Investigators Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial JAMA 287 2002 1531 1540
19. Gheorghiade M., Gattis W.A., and O'Connor C.M. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial JAMA 291 2004 1963 1971 (Pubitemid 38544277)
20. Udelson J.E., Orlandi C., and Ouyang J. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial J Am Coll Cardiol 52 2008 1540 1545
21. Udelson J.E., McGrew F.A., and Flores E. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction J Am Coll Cardiol 49 2007 2151 2159 (Pubitemid 46817812)
22. Coletta A.P., and Cleland J.G. Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology-WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME Eur J Heart Fail 3 2001 747 750 (Pubitemid 33123176)
23. Torre-Amione G., Young J.B., and Colucci W.S. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure J Am Coll Cardiol 42 2003 140 147 (Pubitemid 36760775)
24. O'Connor C.M., Gattis W.A., and Adams K.F. Jr Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4) J Am Coll Cardiol 41 2003 1452 1457 (Pubitemid 36543358)
25. Kaluski E., Kobrin I., and Zimlichman R. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study J Am Coll Cardiol 41 2003 204 210 (Pubitemid 36092185)
26. Nieminen M.S., Akkila J., and Hasenfuss G. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure J Am Coll Cardiol 36 2000 1903 1912
27. Slawsky M.T., Colucci W.S., and Gottlieb S.S. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators Circulation 102 2000 2222 2227
28. Cleland J.G., Freemantle N., and Coletta A.P. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE Eur J Heart Fail 8 2006 105 110 (Pubitemid 43012109)
29. Kivikko M., Lehtonen L., and Colucci W.S. Sustained hemodynamic effects of intravenous levosimendan Circulation 107 2003 81 86 (Pubitemid 36070937)
30. Moiseyev V.S., Poder P., and Andrejevs N. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN) Eur Heart J 23 2002 1422 1432 (Pubitemid 36285574)
31. Mebazaa A., Nieminen M.S., and Packer M. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial JAMA 297 2007 1883 1891 (Pubitemid 46707842)
32. Follath F., Cleland J.G., and Just H. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial Lancet 360 2002 196 202 (Pubitemid 34804646)
33. Cleland J.G., Ghosh J., and Freemantle N. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure Eur J Heart Fail 6 2004 501 508 (Pubitemid 38746595)
34. Garratt C.P.M., Colucci W., and Fisher L. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE I study (abstract) Presented at: 24th International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium 2004 http://ccforum.com/content/8/S1/P89
35. Earl G.L., and Fitzpatrick J.T. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure Ann Pharmacother 39 2005 1888 1896 (Pubitemid 41527702)
36. Givertz M.M., Massie B.M., and Fields T.K. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance J Am Coll Cardiol 50 2007 1551 1560 (Pubitemid 47532320)
37. Dittrich H.C., Gupta D.K., and Hack T.C. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment J Card Fail 13 2007 609 617 (Pubitemid 47513547)
38. Cotter G., Dittrich H.C., and Weatherley B.D. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment J Card Fail 14 2008 631 640
39. Massie B.M., O'Connor C.M., and Metra M. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure N Engl J Med 363 2010 1419 1428
40. Colucci W.S., Elkayam U., and Horton D.P. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group N Engl J Med 343 2000 246 253 (Pubitemid 30490392)
41. Hernandez A.F., O'Connor C.M., and Starling R.C. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF) Am Heart J 157 2009 271 277
42. Sung N.S., Crowley W.F. Jr., and Genel M. Central challenges facing the national clinical research enterprise JAMA 289 2003 1278 1287 (Pubitemid 37432909)
43. Woolf S.H. The meaning of translational research and why it matters JAMA 299 2008 211 213
44. Cotter G., Kaluski E., and Stangl K. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure Eur J Heart Fail 6 2004 601 609 (Pubitemid 39070514)
45. Blair J.E., Zannad F., and Konstam M.A. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program J Am Coll Cardiol 52 2008 1640 1648
46. Ezekowitz J.A., Hernandez A.F., and Starling R.C. Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF) Am Heart J 157 2009 219 228
47. Gheorghiade M., and Bonow R.O. Heart failure: early follow-up after hospitalization for heart failure Nat Rev Cardiol 7 2010 422 424